All AbMole products are for research use only, cannot be used for human consumption.
AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora with Ki values of 0.36 and 1369 nM for Aurora B and Aurora A respectively.Consistent with inhibition of Aurora B kinase, addition of AZD1152-HQPA to tumor cells in vitro induces chromosome misalignment, prevents cell division, and consequently reduces cell viability and induces apoptosis.
Int J Mol Sci. 2023 Mar 6;24(5):5016.
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
AZD1152-HQPA purchased from AbMole
J Hematol Oncol. 2017 Jun 8;10(1):115.
SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
AZD1152-HQPA purchased from AbMole
. figure 7..jpg) |
Source | Journal of Hematology & Oncology (2017). Figure 7. AZD1152-HQPA (Abmole Bioscience) |
| Method | CCK8 assay | |
| Cell Lines | U251, U87 and U118 cell lines | |
| Concentrations | ||
| Incubation Time | 48 h | |
| Results | Treatment with two other aurora kinase inhibitors, AZD1152 and MLN8237, demonstrated similar results (Fig. 7d). |
| Cell Experiment | |
|---|---|
| Cell lines | HL-60 and U937 cells line |
| Preparation method | Proliferation assay. To evaluate the growth inhibition effects, the sodium 3′-(1-[(phenylamino)-carbonyl-3,4-tetrazolium])-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay was performed according to the manufacturer’s instructions (AbMole) with slight modifications. Cell cycle distribution. Flow cytometric analysis was performed to evaluate the cell cycle distribution. The treated samples were fixed in 80% ethanol, stained with 20 ng/mL propidium iodide (AbMole, M5108), and analyzed using FACSCanto II. |
| Concentrations | 25 nM |
| Incubation time | 0 h, 24 h, 48 h, and 72 h |
| Animal Experiment | |
|---|---|
| Animal models | SW620, Colo205, HCT116 human colorectal tumor xenografts in nude mice |
| Formulation | in Tris buffer pH 9.0 |
| Dosages | 150 mg/kg/day |
| Administration | subcutaneous infusion |
| Molecular Weight | 507.56 |
| Formula | C26H30FN7O3 |
| CAS Number | 722544-51-6 |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Aurora Kinase Products |
|---|
| AT9283
AT9283 is a potent inhibitor of several protein kinases, including Aurora A, Aurora B, Janus kinase 2 (JAK2), JAK3, and ABL. |
| CCT-129202
CCT129202 is an Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μmol/L for Aurora A, Aurora B, and Aurora C, respectively. |
| CYC116
CYC116 is a potent, small molecule inhibitor of Aurora A, B and C with IC50 value of 44, 19 and 65 nM respectively. CYC-116 also inhibits VEGFR2, Src, Lck AND FLT3 with with Kis of 44, 82, 280, 44 nM, respectively. CYC-116 may have broad-spectrum antitumor activity. |
| ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor. |
| MLN8054
MLN8054 is an orally bioavailable, highly selective small molecule inhibitor of Aurora with IC50s of 0.004uM and 0.172uM. for Aurora A and Aurora B. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
